Aelis Farma S.A.
PAR: AELIS.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pier Vincenzo Piazza
- Employees
- 28
- Headquarters
- Bordeaux, France
- IPO year
- 2022
- Market cap
- €17.2M
- Website
- https://www.aelisfarma.com
Loading AELIS…
Loading profile data…Frequently asked questions about AELIS
What does Aelis Farma S.A. (AELIS.PA) do?
Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug can...
Where does AELIS.PA trade?
Aelis Farma S.A. (AELIS.PA) trades on the Euronext Paris.
What sector is AELIS.PA in?
Aelis Farma S.A. (AELIS.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aelis Farma S.A.?
Pier Vincenzo Piazza is the chief executive officer of Aelis Farma S.A. (AELIS.PA).
Where is Aelis Farma S.A. headquartered?
Aelis Farma S.A. is headquartered in France.
Does AELIS.PA pay a dividend?
Aelis Farma S.A. (AELIS.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AELIS.PA go public?
Aelis Farma S.A. (AELIS.PA) completed its initial public offering in 2022.